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Summary 
Background and research question: Diabetic macular oedema (DME) is the 
leading cause of vision loss in the working age population in developed 
countries. Therapeutic approaches so far have been laser photocoagulation 
(current gold standard), intravitreal steroid injections and vitrectomy. In 
this report we address the question whether an alternative treatment ap-
proach, namely vascular-endothelial-growth-factor-inhibitors (anti-VEGF), 
leads to better clinical outcomes and fewer adverse events than current treat-
ments in patients with clinically manifest diabetic macular oedema. 
Methods: We performed a systematic literature search in common medical 
and HTA-databases and synthesised the evidence according to the GRADE-
methodology.  
Results: Overall quality of evidence for efficacy of anti-VEGF in the man-
agement of DME is moderate, while quality of evidence for safety is very 
low. In a proportion of patients (on average 25%) VEGF-inhibitors result in 
better visual acuity than in patients treated with glucocorticoids or with la-
ser photocoagulation. However, the number of injections required for long-
term improvement as well as general long-term efficacy is unknown. While 
neither study demonstrated serious safety problems, evidence is not suffi-
cient to regard the products as safe in patients with DME. Concerning the 
different products, there is slightly stronger evidence supporting ranibizu-
mab compared to bevacizumab, however due to the lack of head-to-head tri-
als, this does not suggest superiority of a single product.  
Conclusion: For some patients with DME, VEGF-inhibitors seem to be a 
more effective short-term treatment than alternative therapies. Evidence is 
not of sufficient quality to confirm safety. A decision on financing should 
take into account the high price-difference between the products and the fact 
that many studies are still ongoing.  
 
 
photocoagulation, 
glucocorticoids and 
vitrectomy are current 
treatments of DME 
is anti-VEGF better and 
safer? 
systematic literature 
search + GRADE 
quality of evidence 
moderate for efficacy 
and very low for safety 
in ¼ of patients short 
term improvement of 
visual acuity; safety 
unclear; no superiority 
of single product 
treatment is beneficial, 
enormous price 
differences to be 
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1 Anti-vascular endothelial growth factor (anti-
VEGF) in the management of diabetic macular 
oedema 
1.1 Background 
Diabetic macular oedema (DME) which is a frequent manifestation of dia-
betic retinopathy is the leading cause of vision loss in the working age popu-
lation in developed countries.  
Within 20 years almost all patients with diabetes type I and 60% with type II 
diabetes develop diabetic retinopathy [1]. The presence of DME has been as-
sociated with longer duration of diabetes (any type), insulin use, high glyco-
sylated haemoglobin levels, proteinuria, hypertension and male gender [2]. 
Prolonged oedema results in irreversible damage and permanent loss of vi-
sion, hence visual impairment among people with diabetes increases with 
age. However, vision impairment due to DME is very much related to how 
well diabetes is controlled.  
According to WHO estimates, in Austria the prevalence of diabetes in adults 
is 130,000 (2.1%). A European study identified a retinopathy prevalence of 
23% in the Austrian sub-sample of patients with diabetes [3]. The preva-
lence of DME is uncertain (international figures range from 3% to 6% of all 
patients with diabetes aged 18+) [4]. This would relate to roughly 4,000 to 
7,800 persons with DME in Austria. A large epidemiological study identified 
macular oedema in 26% of those with diabetic retinopathy [5].  
The pathogenesis of DME is multifactorial. It is mainly caused by a break-
down of the blood-retinal barrier, leading to accumulation of fluid and 
plasma constituents (e.g. lipoproteins) within the inner layers of macula. 
This is accompanied by increased vascular permeability due to the release of 
a protein called vascular endothelial growth factor (VEGF) [6]. 
Therapeutic approaches so far have been laser photocoagulation, intravitreal 
steroid injections and vitrectomy. Among those, laser photocoagulation has 
been the gold standard [7]. However, while laser photocoagulation may pre-
serve vision it has not been successful in improving it [4]. Reviews on in-
travitreal steroid injections have demonstrated temporal improvement on 
visual acuity but this is accompanied with an increased risk of raised in-
traocular pressure and development of cataracts [4]. Finally, RCTs on vitrec-
tomy have shown little effect in patients with DME except for specific sub-
groups [4].  
1.2 Anti-VEGF for diabetic macular oedema 
As an alternative treatment for DME anti-vascular-endothelial growth fac-
tors (anti-VEGF) have been introduced. Different types of anti-VEGF are 
available which have in common that they inhibit VEGF angiogenic activity 
DME leading cause of 
vision loss  
many risk factors 
vision impairment 
strongly related to 
diabetes control 
Austria: 130,000 adults 
with diabetes, ˜23% 
have retinopathy; 
prevalence DME: 3%-
6% in diabetic patients 
breakdown of blood-
retinal barrier and 
vascular permeability 
play major role 
therapy so far: laser, 
glucocorticoids, 
vitrectomy 
mostly stabilisation, not 
improvement of visual 
acuity 
alternative treatment: 
anti-VEGF 
Anti-VEGF 
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by binding to the VEGF protein and thus preventing its receptor activation 
[8]. Ultimately, this should reduce vascular permeability and growth and 
hence, DME. 
Pegaptanib (Macugen®, Eyetech Pharmaceuticals Inc.) is a pegylated ap-
tamer that targets only the VEGF 165 isoform and is currently approved for 
the treatment of neovascular age-related macular degeneration (AMD) [8, 9]. 
Bevacizumab (Avastin®, Genentech Inc.) is a full-length humanised anti-
body that binds to all types of VEGF. It is used in and licensed for tumour 
therapy [8, 9]. 
Ranibizumab (Lucentis®, Genentech Inc.; marketed by Novartis in Europe) 
comes from the same parent molecule as bevacizumab, however, it is a hu-
manised monoclonal antibody fragment that binds all active forms of VEGF-
A and is currently approved for AMD and DME [8]. 
In summary, only ranibizumab has been approved for the treatment in DME 
in Europe. Ranibizumab and bevacizumab were both developed by Genen-
tech (now part of Roche) but Roche-Genentech has not sought a licence for 
eye use of bevacizumab [4]. However, due to the high price of ranibizumab, 
bevacizumab has regularly been used off-label while experimental studies 
are underway. Because bevacizumab has been approved in tumour therapy 
(in a higher dose), it has to be divided into smaller doses for ocular indica-
tions.   
Treatment with anti-VEGF in DME needs to be done in regular intervals 
until the maximum improvement in visual acuity is achieved (stability after 
several monthly controls during treatment). If no improvement is realised 
treatment should be stopped. Re-treatment is recommended if visual acuity 
decreases again after successful treatment [10]. Optimal treatment intervals 
are still subject to evaluation and may differ between the different anti-
VEGF products due to their different molecule-sizes and varying half-time. 
Currently monthly intervals are recommended. 
VEGF inhibitors need to be applied intravitreally under sterile conditions. 
Because regular re-treatment is required, there is an increased long-term 
risk of infections leading to endophtalmitis.  
1.3 Indication and therapeutic aim 
Macular oedema is defined as retinal thickening and oedema involving the 
macula. As has been outlined by the Early Treatment Diabetic Retinopathy 
Study (ETDRS) group, clinically significant macular oedema presents the 
following characteristics: retinal thickening within 500 μm of the centre of 
the fovea, hard exudates within 500 μm of the fovea if associated with adja-
cent retinal thickening, or one or more areas of retinal thickening at least 
1500 microns in diameter that are within one disc diameter (1500 microns) 
of the fovea [7, 11]. 
Diagnostic methods are sit lamp examination with a contact lens, stereo 
photography, flourescein angiography and optical coherence tomography 
[8]. 
3 products: pegaptanib 
(Macugen®), 
bevacizumab 
(Avastin®), 
ranibizumab 
(Lucentis®), 
only RBZ licensed for 
DME, IVB because of 
lower price used off-
label 
regular treatment in 
monthly intervals until 
stable improvement, 
otherwise termination 
intravitreal application 
under sterile conditions 
clinical significant DME 
defined by retinal 
thickening 
several diagnostic 
methods 
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Therapeutic aim of anti-VEGF injections in diabetic macular oedema is to 
improve and stabilize quality of vision and, ultimately, to increase quality of 
life which is severely threatened by visual loss (e.g. severe limitation in daily 
activities like reading, watching TV or driving a car,  increased risk of falls). 
As has been outlined in a previous decision support document [12], the main 
parameter to measure vision is visual acuity (VA) which expresses the ability 
to identify small letters with high contrast at a specified distance. Visual 
acuity ranges from 0.01 to2.5 (logMAR).  
Therapeutic success regarding visual acuity is evaluated by measuring best 
corrected visual acuity (BCVA) before and after treatment. Usually, ETDRS 
(Early Treatment of Diabetic Retinopathy Study)-charts are used for defin-
ing visual acuity. Another frequently used chart to evaluate visual acuity is 
the Snellen-chart. 
Changes are commonly expressed in logMAR (logarithm of minimal angle 
of resolution) lines. 1 ETDRS-line is equivalent to 0.1 logMAR. In other 
words, the magnitude of visual acuity expressed in logMAR decreases with 
increased visual acuity. Alternatively, changes are expressed in ETDRS-
letters.  
For people to experience meaningful improvement, visual acuity needs to be 
improved by a minimum of two to three lines or 10 to 15 letters [4]. Hence, 
statistically significant changes in visual acuity are not necessarily clinically 
relevant. Additionally, from the outcome parameters measured in the stud-
ies, mean values are of less interest than the proportion of patients gaining 
clinically relevant improvement in vision [4, 8]. Moreover, visual acuity does 
not represent quality of vision in general (such as seeing objects with poor 
contrast, how much effort is needed to see clearly etc.).  
For assessing overall vision-related quality of life, specific quality of life 
questionnaires that assess visual functioning (such as VFQ-25) are available. 
It has been demonstrated that a change between 3.6 and 15 points on the 
VFQ-25 corresponds to a three line change in visual acuity in patients with 
age related macular degeneration. Hence, for a clinically relevant improve-
ment a mean increase of at least 3.6 points is required [13]. 
In terms of safety, intraocular adverse events (AE) caused by any injection 
(e.g. endophtalmitis), intraocular problems related to anti-VEGF and sys-
temic adverse events due to leakage of anti-VEGF into the systemic circula-
tion need to be analysed.  
1.4 Estimated volumes and costs 
According to the Austrian application document it is estimated that there 
will be about 12,000 intravitreal applications of anti-VEGF for the defined 
population in 2011 in Austria.  
The unit price for ranibizumab (10 mg/ml injection solution) will be € 
954,64 from March 2011 onwards [14]. Bevacizumab (25 mg/ml) costs 368 €. 
The price of pegaptanib is unknown. Due to the required division into 
smaller doses the price of a single bevacizumab injection is manifold 
cheaper than a single ranibizumab injection. Assuming that bevacizumab 
and ranibizumab are divided into 18-20 doses and three doses respectively, a 
therapeutic aim: 
improvement of quality 
of life by better visual 
acuity  
parameters: visual 
acuity (VA), 
BCVA, ETDRS-letters, 
Snellen-lines 
expressed in logMAR 
meaningful 
improvement: 2-3 lines 
or 10-15 letters 
only of limited value for 
defining overall quality 
of vision  
VFQ-25 for assessing 
vision-related quality of 
life  
local or systemic 
adverse events possible 
12,000 injections 
required 
price per injection 
ranibizumab is 16-fold 
the price of a 
bevacizumab injection 
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single injection of bevacizumab costs 20 € and the price of a single ranibi-
zumab is 320 €.  
 LBI-HTA | 2011 11 
2 Literature search and selection of 
literature 
2.1 Research question 
Does the intravitreal application of vascular-endothelial-growth-factor-
inhibitors (anti-VEGF ) in patients with clinically significant diabetic macu-
lar oedema lead to better clinical outcomes (improved visual acuity) and 
fewer (systemic and local) adverse events (AE) than alternative treatments 
with laser photocoagulation, intravitreal application of glucocorticoids or 
vitrectomy?  
2.2 Inclusion criteria 
Inclusion criteria for study selection are presented in table 2.2-1. 
Table 2.2-1: Inclusion criteria 
Population Patients with clinically significant diabetic macular 
oedema 
Intervention Intravitreal application of vascular endothelial 
growth factor (VEGF) inhibitors (+ laser) 
Control intervention a) Laser photocoagulation 
b) Intravitreal application of glucocorticoids 
c) Vitrectomy 
d) VEGF inhibitors in combination with laser 
e) VEGF inhibitors in combination with glu-
cocorticoids 
Outcomes  a) Clinical outcomes:  improvement of visual 
acuity, quality of life 
b) Adverse events: systemic (cardiovascular 
diseases/events…) and local: ocular pro-
cedure-related (endophtalmitis, inju-
ries,…) or drug-related (inflammatory 
processes, bleedings,…) events 
Study design For efficacy:  RCTs 
For safety:  comparative observational studies and 
large-scale single-arm studies (e.g. registries) 
Follow up: ≥24 weeks 
 
PICO-question 
inclusion criteria for 
study selection 
Anti-VEGF 
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2.3 Literature search 
The systematic literature search was performed on January 25th and 26th, 
2011 in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 NHS EED-DARE-HTA (INAHTA) 
 
An additional search for assessments was undertaken on January 27th, 2011 
on the following websites: 
  
 Canadian Agency for Drugs and Technologies in Health 
(http://www.cadth.ca/index.php/en/home) 
 NIHR Health Technology Assessment programme 
(http://www.hta.ac.uk/) 
 NHS Institute for Health and Clinical Excellence 
(http://www.nice.org.uk/) 
 WHO Health Evidence Network 
(http://www.euro.who.int/en/what-we-do/data-and-evidence/health-
evidence-network-hen) 
No search restrictions (e.g. in terms time period/type) were applied in the 
first systematic search stage. For abstract scanning, only English and Ger-
man references from 2000 to 01/2011 were considered. After removing all 
duplicates, 858 references from the systematic search were available. One 
additional source was retrieved from manufacturers’ information. Via hand-
search we identified another 115 sources so that finally 974 references were 
available. The search strategies can be found in the Appendix 
 
systematic literature 
search in data bases and 
websites 
858 sources via 
systematic search 
handsearch + 
manufacturer: 116  
in total:974 references 
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Records identified through 
database searching  
(n = 858) 
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Additional records identified 
through other sources  
(n = 116) 
Records after duplicates removed  
(n = 974) 
Records screened 
(n = 974) 
Records excluded 
(n = 902)    
Not available: 1 
Not relevant:  901 
Full-text articles assessed for     
eligibility 
(n = 72) 
Full-text articles ex-
cluded, with reasons 
(total n =  61) 
Not fulfilling inclusion cri-
teria due to PICO(S): 
Other population: (9) 
Other intervention: (0) 
Other/no control: (1) 
Other outcome: (1) 
Other study design: (7) 
 
Not English/German: (1) 
Insufficient information 
(30) 
Background literature: 
(12)
Studies included in qualitative 
synthesis 
(n = 11) 
RCTs (11) 
 
 
 
 
2.4 Selection of literature 
Overall, 974 references were available. Relevant references were selected by 
two persons independently. Different selection results were discussed in or-
der to achieve consensus. A third person was involved in cases of uncer-
tainty. The selection process is presented in figure 2.4-1.  
Figure 2.4-1: Selection process according to PRISMA flow chart 
 
literature search 
Anti-VEGF 
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3 Study quality assessment 
Assessment of the internal validity of studies was done by two researchers 
independently. Different results were discussed in order to achieve consen-
sus. A third person was involved in cases of uncertainty. The internal man-
ual  of the LBI-HTA describes the quality criteria in detail [15].    
4 Data extraction 
Data extraction was done by a single researcher. A second researcher inde-
pendently double-checked the data for correctness and completeness.  
4.1 Description of study results 
For answering the research question eleven randomised controlled trials  
(RCT) were available. Six RCTs [16-21] are on bevacizumab from which one 
[19] is used for evaluating adverse events only, because it compares two 
doses of bevacizumab only without a placebo or alternative therapy. Four 
RCTs [22-24] have evaluated efficacy and safety of ranibizumab and one 
trial is on pegaptanib [25]. None of the observational studies fulfilled our in-
clusion criteria.  
Study characteristics and results from RCTs on bevacizumab are presented 
in table 4.1-1. Three studies on bevacizumab include patients with refractory 
DME and the remainder treated therapy-naive patients or both. Patients 
were mainly around 60 years of age. Half of the studies compared bevacizu-
mab with triamcinolone injections or a combination of bevacizumab and tri-
amcinolone and in another half photocoagulation or a combination of pho-
tocoagulation plus bevacizumab was the comparator. One study compared 
bevacizumab with sham-injections. There was no study available that com-
pared intravitreal bevacizumab injections with vitrectomy. Study size ranged 
from 28 to 150 eyes randomised and participants were followed for six to 12 
months. None of the bevacizmab-studies was industry-sponsored. 
Study characteristics and results from RCTs on ranibizumab (four trials) 
and pegaptanib (1 trial) are presented in table 4.1-2. Experimental studies 
on ranibizumab included patients in who the previous treatment had to be at 
least three to six months in the past, while in the pegaptanib-study previ-
ously untreated patients were included. The mean age of the study popula-
tion was slightly above 60. Ranibizumab-studies compared anti-VEFG treat-
ment with either sham-injections or photocoagulation or with a combination 
of ranibizumab injections plus laser. One study compared ranibizumab plus 
prompt or deferred laser with steroid injections or laser only. The compara-
tor in the pegaptanib study was sham injection. Again, no study compared 
intravitreal ranibizumab or pegaptanib with vitrectomy. Study size for the 
ranibizumab and the pegaptanib studies was on average larger than in the 
bevacizumab studies, namely between 126 and 854 eyes. The follow-up pe-
quality assessment 
method 
data extraction 
IVB: 6 RCTs 
RBZ: 4 RCTs 
Pegaptanib: 1 RCT 
IVB: patients with 
refractory DME or 
therapy-naive 
comparator: sham-
injections, 
triamcinolone, laser or 
combination of those 
with IVB 
28 to 150 eyes 
randomised 
RBZ: patients with 
previous treatment but 
not necessarily failure 
comparator: sham-
injection, laser, 
combination laser + 
RBZ 
126 to 854 eyes 
randomised 
pegaptanib: comparison 
with sham 
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riod was six to twelve months. All of the ranibizumab-studies and the pegap-
tanib-study were industry-sponsored. 
We extracted the following outcome parameter from the studies: firstly, data 
on visual acuity were extracted in the way they were presented in the study. 
In the majority of studies mean change in visual acuity described as best cor-
rected visual acuity (BCVA) logMAR or mean changes in ETDRS-letters 
were presented. Some publications additionally showed mean baseline and 
follow-up values.  
Secondly, we extracted information on the proportion of patients with at 
least 10 or 15 letters or two to three lines improvement and on the propor-
tion of patients with 10/15letters or two/three lines worsening. Thirdly, data 
on vision-related quality of life were extracted which were available in one 
study only.  
Finally, we extracted data on adverse events reported. On the one hand, 
these included local AE: ocular procedure-related events such as 
endophtalmitis or injuries, local drug-related events such as inflammatory 
processes or local bleedings. On the other hand, reported systemic adverse 
events such as cardiovascular events or increased blood pressure were ex-
tracted.  
Data on anatomical changes such as central macular thickness that were 
presented in all studies were not extracted because they were regarded as ir-
relevant for patients (see PICO-question chapter 2.2).  
 
extracted outcome 
parameters: mean 
visual acuity  
% of patients who 
achieved ≥15 letters or 
2-3 lines improvement, 
quality of life 
safety: local and 
systemic AE 
anatomical changes not 
extracted 
Anti-VEGF 
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Table 4.1-1:  Results from RCTs on bevacizumab in diabetic macular oedema (significant results in bold) 
Author, year, reference 
number 
Paccola (2008)  [16] Ahmadieh (2008) 
[17] 
Soheilian (2009) [18] Lam (2009) ([19] Solaiman (2010) [20] Michaelides (2010) [21] 
Country Brazil Iran Iran Hong Kong Egypt UK 
Sponsor Non-industry Non-industry Non-industry Non-industry Non-industry Non-industry 
Product/Intervention Arm 1:IVB (1.5mg) single 
dose 
Arm 1: IVB (1.25mg) 
≤3 doses 
Arm 1: IVB (1.25mg) re-treatment at 
12 ws if required 
Arm 1: IVB (1.25mg) 3 
doses 
Arm 1: IVB (1.25mg) single 
dose 
Arm 1: IVB (1.25mg) ≥3 to 9 
doses 
Comparator Arm 2: IVT (4mg) single 
dose 
Arm 2: IVB (1.25mg) 
followed by  2 doses + 
IVT (2mg)  
Arm 3: sham-injection
Arm 2: IVB (1.25 mg) +IVT (2 mg), 
re-treatment if required 
Arm 3: MPC (re-treatment as re-
quired) 
Arm 2: IVB (2.5mg) 3 
doses 
Arm 2: MPC once 
Arm 3: MPC +IVB (1.25mg) 
single dose 
Arm 2: MPC (re-treatment if 
required) 
Study design RCT RCT RCT RCT RCT RCT 
No. of eyes (patients)  
No. randomised per arm 
28(28) 
14/14 
115 (101) 
41/37/37 
150 (129) 
50/50/50 
52 (52) 
26/26 
62 (48) 
19/21/22 
80 (80) 
42/38 
Inclusion criteria Refractory DME 
ETDRS BCVA: 0.3 (20/40 
Snell. equival.) or worse  
CMT: ≥300μm 
Refractory DME 
VA: 20/40 or worse, 
CMT not stated 
Untreated DME  
VA: 20/40-20/300  
DME treated 
≥6ms/untreated 
VA (logMAR): 1.3 and 
better 
CMT: ≥250μm 
Untreated diffuse DME      
CMT: ≥350μm 
Refractory DME 
VA: 6/12-6/60                 
CMT: ≥270μm  
Age of patients per group   66/67 60 (mean  age) 61/62/61 65/66 56/57/59 65/64 
Follow up  24 ws (6 ms) 24 ws (6 ms) 24 ws/6 ms (prim. outcome) 
36 ws (9 ms) (sec. outcome) 
24 ws (6 ms) 24 ws (6 ms) 24 ms (this study = 12-ms re-
sults) 
Drop-out rate 1/28 (IVB) 
1/28 (IVT)  
Not stated 6/50 (IVB) 
12/50 (IVB/IVT) 
7/50 (MPC) 
3/26 (IVB 1.25mg) 
1/26 (IVB 2.5mg) 
Not stated 0/42 (IVB) 
2/38 (MPC) 
 
Efficacy 
      
LogMAR BCVA 
Within arm: mean at base-
line/follow-up (mean dif-
ference, p-value) 
 
Between arm: mean dif-
ference (p value) 
 
24 ws ± 
1) 0.9375/0.9125             
(-0.025, n.s.) 
2) 0.9366/0.9233            
(-0.0133, n.s.) 
 
IVB/IVT:-0.1 (n.s.) 
24 ws ±± 
1) -0.18 
2) -0.21 
3) -0.03 
 
 
Sham/IVB: 0.21       
(p 0.010) 
Sham/IVB + IVT: 0.24  
(p 0.006) 
IVB/IVB +IVT: 0.02    
(p 0.999) 
24ws; 36 ws ±± 
1) 0.23;0.28 (p 0.001/0.001) 
2) 0.07;0.04 (p 0.178/0.057)  
3) 0.01;0.01 (p 0.858/0.865) 
 
 
IVB/IVB+IVT: 0.16 (24 ws) 
                         0.24 (36 ws) 
IVB/MPC: 0.22 (24 ws) 
                  0.27 (36 ws) 
(P 24 ws: 0.012; 36 ws: 0.053) 
24 ws ± 
1) 0.63/0.52 (-0.11; p 
0.018) 
2) 0.60/0.47 (-0.13; p 
0.003) 
 
IVB1/IVB2: -0.02 (p 
0.79) 
24 ws  
1) 0.84/0.82 (-0.02, n.s.) 
2) 0.84/0.85 (+0.01, n.s.) 
3) 0.83/0.74 (-0.09, n.s.) 
 
 
IVB/MPC: 0.03 (n.s.) 
MPC+IVB/IVB: -0.07 (n.s.) 
1 yr*  
1) 55.7/61.3 (+5.6/+8# letters) 
2) 54.6/50.0 (-4.6/-
0.5#letters) 
  
 
IVB/MPC: +11.3 letters 
(p 0.006) 
median change: 
IVB/MPC: +8.5 letters  
(p 0.002) 
 LBI-HTA | 2011 17 
Author, year, reference 
number 
Paccola (2008)  [16] Ahmadieh (2008) 
[17] 
Soheilian (2009) [18] Lam (2009) ([19] Solaiman (2010) [20] Michaelides (2010) [21] 
 
% 2 lines gain±±  
% unchanged 
% 2 lines loss 
 
  24ws;36 ws 
31/21/11; 37/25/15 
69/64/66;59/54/68 
0/15/23;4/21/19 
(p 24 ws: 0.014; 36 ws 0.164) 
   
% ≥15 ETDRS letters gain 
% ≥10 ETDRS letters gain 
% <15 ETDRS letters loss 
% ≥30 ETDRS letters loss 
     11.9/5.3 (p 0.43) 
31.0/7.9 (p 0.01) 
97.6/73.7 (p 0.01) 
0/5.3 (p 0.22) 
 
Adverse events 
      
Local (yes/no) 
Systemic (yes/no) 
SAE (yes/no) 
Yes 
No 
No 
Yes 
No 
Yes 
Yes 
No 
Yes 
No 
No 
Yes 
No 
Not stated 
Not stated 
Yes: 20(42)/8(38) 
Yes: 4(42)/3(38) 
Yes: 3(42)/7(38) 
Description of SAE per arm  Death 
0(41)/0(37)/1(37) 
Vitreous haemor-
rhage: 
0(41)/1(37)/0(37) 
Death 0(50)/2(50)/2(50) 
Progress to high-risk PDR: 
4(50)/3(50)/3(50) 
Foot gangrene requir-
ing amputation 
1(26)/0(26) 
 Foot ulcer 1(42)/1(38) 
Cholecystectomy 1(42)/0(38) 
Fall 0(42)/1(38) 
Worsening angina 0(42)/1(38) 
CVI 0(42)/1(38) 
IOP ≥45mmHg 1(42)/0(38) 
Vitreous haemorrhage 
0(42)/1(38) 
Description of AE 
1) Transient chamber reac-
tion 
2) Ocular hypertension 
3) Lens opacity 
4) Retinal neovasc. 
5) Early PDR 
6) Retinal detachment 
2) significant increase of 
IOP in IVT-group at week 4 
 
1) 1(41)/0(37)/0(37) 
2) 0(41)/3(37)/0(37) 
3) 0(41)/0(37)/0(37) 
4) 0(41)/0(37)/0(37) 
5) 1(41)/0(37)/0(37) 
 
1) 10(50)/9(50)/0(50) 
2) 0(50)/8(50)/0(50) 
3) 0(50)/4(50)/1(50) 
4) 4(50)/2(50)/3(50) 
5) 1(50)/4(50)/3(50) 
6) 0(50)/2(50)/2(50) 
 
   
 
 
AE: adverse events; BCVA: best corrected visual acuity; diff.: difference; CMT: central macular thickness; DME: diabetic macular edema; ETDRS: Early Treatment Diabetic Retinopathy Study; IVB: 
intravitreal bevacizumab; IVT: intravitrial triamcinolone; logMAR: logarithm of the minimal angle of resolution; MPC: macular laser photocoagulation; ms: months; n.s.: not significant; PDR: prolif-
erative diabetic retinopathy; RCT: randomised controlled trial; SAE: serious adverse event; VA: visual acuity; ws: weeks; *ETDRS letters; ±ETDRS chart; ±±Snellen chart; # median change 
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Table 4.1-2: Results from RCTs on ranibizumab and pegaptanib in diabetic macular oedema (significant results in bold) 
Author, year, reference 
number 
Nguyen (2009) [22] Massin (2010) [23] DRCRN (2010)  [24] Novartis study (2011) [26] MDRSG (2005) [25]  
Country USA (multicenter) Europe (multicenter) USA (multicenter) Europe+Australia+Canada+NZ International (multicenter) 
Sponsor Genentech Novartis Genentech+Allergan Novartis Eyetech Pharmaceuticals, Pfizer 
Product/Intervention  Arm 1: RBZ (0.5mg) 4 doses Arm 1: RBZ (0.3-0.6mg)  
Arm 2: RBZ (0.5-1.0mg) 
3 monthly 
Arm 1: RBZ (o.5mg) ≥3 doses + 
prompt MPC 
Arm 2: RBZ (o.5mg) ≥3 doses + 
deferred MPC 
Arm 1: RBZ (0.5mg) ≥3 doses + 
sham MPC;  
 
Arm 1: Pegaptanib (PG) (0.3mg) 
Arm 2:PG (1mg) 
Arm 3:PG (3mg) ≥3 doses 
Comparator Arm 2: MPC baseline + ms  3 
Arm 3: RBZ (0.5mg)  2 doses + MPC 
Arm 3: sham Arm 3: IVT (4mg)  every 4 ws + 
prompt MPC 
Arm 4: sham + prompt MPC 
Arm 2: RBZ (0.5mg) ≥3 doses + 
MPC  
Arm 3: MPC + sham RBZ 
Arm 4: sham 
Study design RCT RCT RCT RCT RCT 
No. of eyes (patients)  
No. randomised per arm 
126(126) 
42/42/42 
151 (151) 
102/49 
854 (691) 
187/188/186/293 
345 (345) 
116/118/111 
172 (172) 
44/44/42/42 
Inclusion criteria DME treated >3ms/untreated 
VA: 20/40 to 20/320 
CMT: ≥250 μm 
DME treated >6ms/ untreated 
VA: 20/40 to 20/160 
CMT: ≥300 μm 
DME treated >4ms/untreated 
VA: 20/32 to 20/320 
CMT: 250 μm 
Focal or diffuse DME >3 to 6ms 
treated/untreated 
VA: 20/32 to 20/160 
DME untreated 
VA: 20/50 to 20/230 
CMT: not stated 
Age of patients per group 62/62/62 63/63/65 62/64/62/63 63/64/64 62/63/61/64 
Follow up  24 ws (6 ms)  12 ms Prim. outc: 12 ms (3 yrs planned) 12 ms 36 ws (9 ms) 
Drop-out rate 5/42 (RBZ) 
4/42 (MPC) 
2/42 (RBZ + MPC) 
10/102 (RBZ groups) 
9/49 (sham) 
16/187 (RBZ + MPC) 
19/188 (RBZ  + def. MPC) 
10/178 (IVT + MPC) 
19/293 (sham + MPC) 
14/116 (RBZ + sham MPC) 
15/118 (RBZ + MPC) 
13/111 (MPC+ sham RBZ) 
0/44 (PG 0.3mg) 
0/42 (PG 1mg) 
3/42 (PG 3mg) 
6/41 (sham)  
 
Efficacy 
     
BCVA (ETDRS letters) 
Within arm: mean at 
baseline/follow-up (mean 
difference) 
 
 
Between arm: mean dif-
ference (p value) 
 
6 ms  
1) +7.24 letters 
2) -0.43 letters 
3) +3.8 letters  
 
 
RBZ/MPC: 6.81 (p 0.001) 
RBZ/RBZ + MPC: 3.44 (p 0.08) 
RBZ + MPC/MPC: 4.23 (n.s.) 
1 yr  
1) 59.2/70.9 (+11.8 letters) 
2) 61.2/70 (+8.8 letters) 
3) 61.1/59.7 (-1.4 letters) 
 
 
RBZ1/sham: 13.4 (p <0.0001) 
RBZ2/sham: 10.6 (p <0.0001) 
 
1 yr  
1) +9 letters 
2) +9 letters 
3) +4 letters 
4) +3 letters 
: 
RBZ+prompt MPC/MPC: 5.8      
(p 0.001) 
RBZ+defer. MPC/MPC: 6         
(p 0.001) 
IVT+prompt MPC/MPC: 1.1         (p 
0.31) 
1 yr 
1) 64.7/71.5 (+6.8 letters)  
2) 63.4/69.7 (+6.4 letters) 
3) 62.6/63.4 (+0.9 letters) 
 
 
RBZ/MPC: 6.2 (p <0.001) 
RBZ+MPC/MPC: 5.4 (p0.004) 
9 ms  
1) +4.7 letters 
2) +4.7 letters 
3) +1.1 letters 
4) +0.4 letters 
 
0.3mg PG/sham:4.3 (p 0.04) 
1mg PG/sham: 4.3 (p 0.05) 
3mg PG/sham: 0.7 (p0.55) 
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Author, year, reference 
number 
Nguyen (2009) [22] Massin (2010) [23] DRCRN (2010)  [24] Novartis study (2011) [26] MDRSG (2005) [25]  
% ≥3 lines gain 
 
 
% ≥2 lines gain 
22/0/8 
RBZ/MPC: +22%-points (p 0.002) 
RBZ+MPC/MPC: +14%-points (p?) 
46/5/30 
RBZ/MPC: +41%-points (p 0.00004) 
RBZ+MPC/MPC: +16%-points          
(p 0.007) 
   18/14/7/7 
% ≥10 letters gain 
 
 
 
% ≥10 letters loss 
 
 
 
% ≥15 letters gain 
 
 
 
% ≥15 letters loss 
 37/25/9 
 
 
 
0/5/12 
RBZ1/sham: (p <0.0001) 
RBZ2/sham: (p 0.001) 
 
18/15/5 
 
 
 
0/3/10 
RBZ1/sham (p 0.0001) 
RBZ2/2sham (p 0.0037) 
20/19/12/13 
RR1*/MPC: 1.84 (p 0.001) 
RR2/ MPC: 1.68 (p 0.001) 
RR3/ MPC: 1.21 (p 0.16) 
2/1/6/5 
RR1/ MPC: 0.24 (p 0.001) 
RR2/ MPC: 0.24 (p 0.001) 
RR3/ MPC: 1.08 (p 0.75) 
30/28/21/15 
RR1/ MPC: 2.09 (p 0.001) 
RR2/ MPC: 1.89 (p 0.001) 
RR3/ MPC: 1.43 (p 0.07) 
2/2/8/8 
RR1/ MPC: 0.21 (p 0.009) 
RR2/ MPC: 0.28 (p 0.01) 
RR3/ MPC: 1.02 (p 0.95) 
37/43/16 
RBZ/MPC: (p<0.0001) 
RBZ+MPC/MPC: (p<0.001) 
 
4/4/13 
 
 
 
23/23/8 
RBZ/MPC: (p 0.0032) 
RBZ+MPC/MPC: (p 0.0021) 
 
1/3/8 
 
Visual functioning (VFQ-
25 ) mean baseline/follow-
up 
 
Difference between 
groups 
   1) 72.8/77.8 (5.0) 
2) 74.1/79.5 (5.4) 
3) 73.5/74.1 (0.6) 
 
RBZ/MPC: 4.1 (p 0.0137) 
RBZ+MPC/MPC: 4.7 (p 0.0041) 
 
Adverse events     
 
 
Local (yes/no) 
Systemic (yes/no) 
SAE (yes/no) 
Yes 
No 
Yes 
Yes 80(102)/28(49) 
Yes 14(102)/6(49) 
Yes 
Yes 
Yes 
Yes 6(187)/2(188)/13(178)/6(293) 
Yes 49(115)/51(120)/43(110) 
Yes 67(115)/55(120)/68(110) 
Yes 33 (115)/24 (120)/22(110) 
Yes 38(44)/34(42)/37(42)/30(41) 
No  
Yes 6(44)/2(42)/13(42)/6(41) 
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Author, year, reference 
number 
Nguyen (2009) [22] Massin (2010) [23] DRCRN (2010)  [24] Novartis study (2011) [26] MDRSG (2005) [25]  
Description of SAE per 
arm 
Death (0(42)/0(42)/1(42) 
Vitreous haemorrhage 
1(42)/4(42)/3(42) 
Vitreous haemorrhage 
1(51)/0(51)/0(49) 
Retinal ischaemia 
0(51)/1(51)/0(49) 
Retinal artery occlusion  
0(51)/1(51)/0(49) 
Endopthalmitis 
1(51)/1(51)/0(49) 
Retinal detachment 
0(51)/0(51)/1(49) 
Metabolism/nutrition 
2(51)/1(51)/1(49) 
Infections 1(51)/1(51)/3(49) 
Urinary bladder cancer 
1(51)/0(51)/0(49) 
Arterial thromboembolic 
events 0(51)/3(51)/2(49) 
Non-ocular haemorrhage 
1(51)/1(51)/0(49) 
Ocular vascular event 
1(187)/0(188)/2(186)/1(273) 
Endophtalmitis 
1(187)/1(188)/0(186)/0(273) 
Retinal detachment 
0(187)/1(188)/0(186)/0(273) 
Vitrectomy 
0(187)/3(188)/0(186)/7(273) 
Vitreous haemorrhage 
3(187)/4(188)/2(186)/15(273) 
 
Non-fatal MI 
1(RBZ)/2(IVT)/3(sham) 
Non-fatal cerebrovasc. event 
3(RBZ)/1(IVT)/5(sham) 
Vascular death 
7(RBZ)/2(IVT)/4(sham) 
Any ATC event 
11(RBZ)/5(IVT)/10(sham) 
Death  2(115)/2(120)/2(110) 
Cardiac disorders 
8(115)/4(120)/4(110) 
Gastrointestinal disorders 
3(115)/3(120)/2(110) 
Infections 6(115)/3(120)/3(110) 
Metabolism and nutrition 
4(115)/2(120)/3(110) 
Nervous system 
5(115)/1(120)/2(110) 
Respiratory, thoracic 
4(115)/2(120)/2(110) 
Vascular disorders 
4(115)/2(120)/3(110) 
Ocular study eye 
(0(115)/2(120)/2(110) 
Ocular fellow eye 
3(115)/1(120)/2(110) 
Endophtalmitis 0.15% per injec-
tion or 0.8 % per subject 
Description of AE 
1) Ocular hypertension 
2) Blood pressure increase 
3) Non-ocular AE 
4) Glaucoma surgery 
5) Cardiac disorders 
 2) 4(51)/5(51)/5(49) 
3) 64(102)/32(49) 
 
1) 10(187)/5(188)/70(178)/16(293)
4) 0(187)/0(188)/0(178)/0(293) 
 
Number of events per injection 
2) 16(710 RBZ)/6(369 IVT)/0(319 
sham) 
5) 17(710 RBZ)/13(369 IVT)/12(319 
sham) 
 
 
 
 
AE: adverse event; BCVA: best corrected visual acuity; CMT: central macular thickness; DME: diabetic macular edema; ETDRS: early treatment of diabetic retinopathy study group; IVT: Intravitreal 
Triamcinolone; MPC: macular laser photocoagulation; ms: months; PG: Pegaptanib; Prim. outc.: Primary outcome; RCT: randomised controlled trial; RBZ: Ranibizumab; SAE: serious adverse event; 
ws: weeks; yrs.: years; *difference in proportion from sham /relative risk 
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4.2 Efficacy  
Table 5-1 presents the efficacy results of anti-VEGF compared to alternative 
treatments. 
Bevacizumab 
Current evidence on the efficacy of intravitreal bevacizumab (IVB) com-
pared to sham injections shows that IVB significantly improves mean visual 
acuity, however the single study available does not provide information on 
the proportion of patients in which gains in letters was clinically relevant 
and on long-term effects.   
Studies that compare IVB with laser photocoagulation have shown higher 
and clinically relevant gains (up to one year follow-up) in mean visual acuity 
in IVB-patients than in those who received photocoagulation (partly signifi-
cant). A higher proportion of patients (max. 37%) in the IVB-groups 
achieved a clinically relevant gain in letters; however significance of this dif-
ference was unclear.  
Studies did not demonstrate a difference between IVB and intravitreal ster-
oids, yet there is only one trial with short follow-up and a small study popu-
lation available. 
Similarly, studies did not demonstrate a significant and clinically relevant 
difference between IVB alone or with triamcinolone. The proportion of pa-
tients that gained at least two Snellen lines is lower in patients that receive 
IVB plus triamcinolone and more people in the combined group lost  ≥2  
lines, yet the difference is not significant. 
Finally, no difference was demonstrated when comparing IVB alone or in 
combination with laser photocoagulation. Yet, quality of evidence in this 
case is very low and the outcome ‘percentage of patients that gain/loose ≥10 
or 15 letters’ has not been measured. 
No information is available on the improvement in vision related quality of 
life in bevacizumab studies. 
Ranibizumab 
A single and high quality study on the efficacy of intravitreal injections of 
ranibizumab (RBZ) compared to sham injections showed that after one year 
RBZ significantly improved mean visual acuity and the percentage of pa-
tients gaining at least 15 letters was significantly higher in the RBZ-group 
(max. 18%) than in the sham-injection group. Vice versa, the proportion of 
those who lost ≥15 letters was lower in the RBZ-group than in the sham-
injection group. Those who received the lower RBZ-dose did better than 
those with the higher dose. 
Additionally, studies demonstrated a significant but not clinically relevant 
higher mean visual acuity in the RBZ groups compared to laser photocoagu-
lation. However, clinically relevant efficacy has been demonstrated by show-
ing that around 23% compared to a maximum of 8% gained at least 15 let-
ters in the RBZ and photocoagulation groups respectively. This difference is 
statistically significant. Fewer patients in the RBZ group compared to those 
who received photocoagulation lost ≥15 letters, yet significance is unclear 
and only one study was available on that outcome parameter. Finally, pa-
IVB vs. sham: improved 
mean VA in 6 months 
IVB vs. laser: partly 
significant and relevant 
improvement of mean 
VA 
IVB vs. glucocorticoids: 
no difference 
IVB vs. IVB + 
glucocort.: no 
difference 
IVB vs. IVB + laser: no 
difference, important 
outcomes not measured 
no info on quality of life 
RBZ vs. sham: more 
patients (max. 18%) 
achieved ≥15 letters 
RBZ vs. laser: more 
patients (max. 23%) 
achieved ≥15 letters 
 
higher quality of life in 
RBZ group 
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tients in the RBZ-group achieved a higher improvement in vision related 
quality of life than those in the laser group. 
No evidence is available on the comparison between RBZ and intravitreal 
steroids or on the comparison between RBZ alone or in combination with in-
travitreal steroids. 
One study that compared RBZ alone or in combination with laser demon-
strated a higher but not clinically relevant gain in mean visual acuity in the 
‘RBZ-only’ group.  
Finally, it has been evaluated whether RBZ in combination with prompt or 
deferred laser results in better outcomes than providing laser only. A signifi-
cantly higher proportion (max. 30%) in the combined group with prompt la-
ser gained ≥15 letters compared to the ‘laser-only’ group (max. 15 %). Addi-
tionally, the combined group achieved a higher improvement in vision re-
lated quality of life. The combination of RBZ with deferred laser demon-
strated also better results than the ‘laser-only’ group, yet the improvement 
was lower than with prompt laser.   
Pegaptanib 
The single study available demonstrates results in the direction of better 
visual acuity with intravitreal pegaptanib compared to sham injections, 
however differences were either not clinically relevant or of unknown sig-
nificance. No evidence is available on improvement in vision related quality 
of life in pegaptanib trials. 
Head-to-head comparisons 
No evidence is available on the comparative effectiveness between the three 
products (head-to-head trial). 
4.3 Safety  
According to the safety data in the studies (table 5-2), ocular events have 
been the most frequent adverse events stated. In up to 50% of eyes treated 
with bevacizumab, in up to 80% of the ranibizumab-treated eyes, in up to 
53% of laser-treated eyes and in up to 70% in eyes with sham-injections ocu-
lar adverse events were registered. In 43% of patients who received ranibi-
zumab plus laser, ocular adverse events were reported. However, most of the 
ocular adverse events are none-serious (e.g. eye pain, red eyes, transient in-
creased intraocular pressure).  
Most frequent ocular serious adverse events stated were seriously increased 
intraocular pressure (<1% in bevacizumab; 5% in laser eyes; 8-16% in com-
bined group of bevacizumab plus triamcinolone), vitreous haemorrhage (1% 
in ranibizumab-eyes; up to 9% in laser-treated eyes) and endophtalmitis (2% 
in ranibizumab-treated eyes; <1% in pegaptanib-treated eyes). 
RBZ vs. glucocort.: no 
data 
RBZ vs. RBZ + laser: 
higher but not relevant 
VA 
RBZ + prompt laser 
better than laser only 
less improvement with 
RBZ + deferred laser  
pegaptanib vs. sham: 
tendency for 
improvement but 
evidence unclear 
no head-to-head trials 
available 
local events most 
common AE in all 
groups  
mainly minor AE 
SAE: intraocular 
pressure, vitreous 
haemorrhage, 
endophtalmitis 
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Additionally, studies reported systemic adverse events in one bevacizmab-
study (4%), max. 60% in ranibizumab-treated and laser-treated patients, in 
12% of patients post sham-injections and in 46% of patients who received 
ranibizumab plus laser. In some cases, relation to the treatment is very 
unlikely (e.g. metabolic events, cholecystectomy). Cardio-vascular events 
were reported in 7% of patients treated with ranibizumab and in 1%-4% of 
those treated with laser. 2% (2) of the patients in the ranibizumab-groups, 
4% (2) of patients in the laser groups, 2% (1-2) of those in the ranibizumab 
+ laser groups and 3% (1) of patients in the sham group died.  
Overall proportions of serious adverse events reported ranged from 29% in 
patients treated with ranibizumab, 22% in those treated with laser to 15% in 
patients who received sham-injections.  
5 Quality of evidence 
For assessing the quality of evidence we apply the concept by the GRADE 
working group [27]. GRADE uses the following classification and definitions 
for assessing the quality of the evidence:  
 High: further research is very unlikely to change our confidence in the 
estimate of effect  
 Moderate: further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the estimates 
 Low: further research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to change the es-
timate 
 Very low: we are very uncertain about the estimate  
Application of the GRADE-Scheme for our research question is presented 
in tables 5-1 and 5-2. Overall quality of evidence for the efficacy of anti-
VEGF in the management of DME is moderate. Quality of evidence is 
higher for ranibizumab efficacy than for bevacizumab or pegaptanib effi-
cacy. Quality of evidence for safety of any anti-VEGF product in the man-
agement of DME is very low.  
  
up to 60% systemic AE 
cardio-vascular AE: 
max. 7% in anti-VEGF 
groups 
relation to treatment 
often unclear 
total SAEs: 20% in RBZ, 
22% in laser, 15% in 
sham-group 
quality of evidence 
according to GRADE 
efficacy: moderate 
quality of evidence; 
RBZ higher than IVB 
safety: very low quality 
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Table 5-1: Evidence profile: efficacy of anti-VEGF versus comparators 
No of studies/eyes/patients Design Limitations Consistency of results Directness Effect size Other modifying fac-
tors* 
Quality of evi-
dence 
Outcome: mean change visual acuity (logMAR) Bevacizumab (IVB); between groups difference 
IVB/IVT:1/28/28 
IVB/IVT+IVB: 2/265/230 
IVB/MPC: 2/212/177 
IVB/MPC+IVB: 1/62/48 
IVB/sham: 1/114/101 
RCT 
RCT 
RCT 
RCT 
RCT 
No ser. limit. 
Ser. limit.## 
Ser. limit.± 
Ser. limit.± 
No ser. limit. 
Only 1 trial 
Consistent 
No import.  inconsist. 
Only 1 trial 
Only 1 trial 
Some uncertainty# 
Direct 
Some uncertainty# 
Some uncertainty# 
Some uncertainty 
-0.0117 better; not significant  
IVB+IVT -0.02 to -0.24 better; not significant 
-0.03 to -0.27 better; one study significant, one not 
IVB+MPC: -0.07 better; not significant 
-0.21 better; significant, clinically relevant 
Sparse data/low prec. 
- 
- 
- 
- 
Low 
Moderate 
Low 
Low 
Low 
Outcome: mean change visual acuity (logMAR) Ranibizumab (RBZ) and Pegaptanib (PG);  between groups difference 
Not measured 
Outcome: visual acuity (mean change ETDRS-letters) Bevacizumab (IVB); between groups difference 
IVB/MPC: 1/80/80 RCT No limit. Only 1 trial Direct +11.3 significant, clinically relevant - High 
Outcome: visual acuity (mean change ETDRS-letters) Ranibizumab  (RBZ);  between groups difference 
RBZ/MPC: 2/471/471 
RBZ/MPC+RBZ: 1/126/126 
RBZ/sham: 1/151/151 
RBZ+MPC/MPC: 3/1325/1162 
RBZ+def. MPC/MPC: 1/854/691
RCT 
RCT 
RCT 
RCT 
RCT 
Ser. limit.±± 
Ser. limit. ¤¤ 
No ser. limit. 
Ser. limit. ±± 
Ser. limit.† 
Consistent 
Only 1 trial 
Only 1 trial 
consistent 
Only 1 trial 
Direct 
Direct 
Some uncertainty 
Direct 
Direct 
+6.2 to +6.8; significant, not clinic. relevant 
+3.4; not significant 
+10.6 (h. dose) to +13.4 (l. dose); sign., clinic. relev. 
+3.8 to +5.8; 2 sign., 1 not; not clinic. relevant 
+6; significant, not clinic. relevant 
- 
- 
- 
- 
- 
Moderate 
Low 
Moderate 
Moderate 
Moderate 
Outcome: visual acuity (mean change ETDRS-letters) Pegaptanib (PG);  between groups difference 
PG/sham: 1/172/172 RCT Serious 
limit.†† 
Only 1 trial Direct 0.7 (high dose; not sign.) to 4.3 (sign.); not clinic. rel. - Moderate 
Outcome: proportion of ≥15 ETDRS letters or ≥2 Snellen-lines gain Bevacizumab (IVB) 
IVB/IVT: 1/28/28 
IVB/IVT+IVB: 1/150/129 
IVB/MPC: 2/230/209 
IVB/MPC+IVB: 1/62/48  
IVB/sham: 1/115/101 
RCT 
RCT 
RCT 
RCT 
RCT 
- 
Ser. limit.## 
Ser. limit.## 
- 
- 
 
Only 1 trial 
Consistent 
 
 
 
Direct 
Some uncertainty# 
 
Not measured 
Range: 31%-37%/21%-25%; significance unclear 
Range: 12%-37%/5%-15%; significance unclear 
Not measured 
Not measured 
- 
- 
- 
- 
- 
- 
Moderate 
Low 
- 
- 
Outcome: proportion of ≥15 ETDRS letters or ≥3 Snellen-lines gain Ranibizumab (RBZ) 
RBZ/MPC: 2/471/471 
RBZ/MPC+RBZ: 1/126/126 
RBZ/sham: 1/151/151 
RBZ+MPC/MPC: 3/1325/1162 
RBZ+def. MPC/MPC: 1/854/691
RCT 
RCT 
RCT 
RCT 
RCT 
Ser. limit.±± 
Ser. limit. ¤¤ 
No ser. limit. 
Ser. limit. ±± 
Ser. limit.† 
Consistent 
Only 1 trial 
Only 1 trial 
Consistent 
Only 1 trial 
Direct 
Direct 
Some uncertainty 
Direct 
Direct 
Range: 22%-23%/0%-8%; significant 
22%/8%; significance unclear 
15% (higher dose) -18% (lower dose)/5%; significant 
Range: 8% to 30%/0% to 15%; RR 2.09; significant 
28%/15%; RR 1.89; significant 
- 
- 
- 
- 
- 
Moderate 
Low 
High 
Moderate 
Moderate 
Outcome: proportion of ≥15 ETDRS letters or ≥3 Snellen-lines gain Pegaptanib (PG) 
PG/sham: 1/172/172 RCT Serious 
limit.†† 
Only 1 trial Some uncertainty 7% (h. dose) -18% (l. dose) to 7% (sham); signifi-
cance unclear 
- Moderate 
Outcome: proportion of ≥15 ETDRS letters or ≥2 Snellen-lines loss Bevacizumab (IVB) 
IVB/IVT: 1/26/26 
IVB/IVT+IVB: 1/150/129 
IVB/MPC: 2/230/209 
IVB/MPC+IVB: 1/62/48  
IVB/sham: 1/115/101 
RCT 
RCT 
RCT 
RCT 
RCT 
- 
Ser. limit.## 
Ser. limit.## 
- 
- 
 
Only 1 trial 
Consistent 
 
 
Direct 
Some uncertainty# 
 
Not measured 
Range: 0%-4%/15%-21%, not significant 
Range: 0%**-4%/5%**-23%; not significant 
Not measured 
Not measured 
- 
- 
- 
- 
- 
- 
Moderate 
Low 
- 
- 
 
 LBI-HTA | 2011 25 
No of studies/eyes/patients Design Limitations Consistency of results Directness Effect size Other modifying fac-
tors* 
Quality of evi-
dence 
Outcome: proportion of ≥15 ETDRS letters or ≥2 Snellen-lines loss Ranibizumab (RBZ) 
RBZ/MPC: 1/345/345 
RBZ/MPC+RBZ: 1/126/126 
RBZ/sham: 1/151/151 
RBZ+MPC/MPC: 2/1199/1036 
RBZ+def. MPC/MPC: 1/854/691
RCT 
RCT 
RCT 
RCT 
RCT 
Ser. limit.¤ 
- 
No ser. limit. 
Ser. limit.†, ¤ 
Ser. limit.† 
Only 1 trial 
 
Only 1 trial 
Consistent 
Only 1 trial 
Direct 
 
Some uncertainty 
Direct 
Direct 
1%/8%; significance unknown 
Not measured 
Range: 0%-3%/10%; significant 
Range: 2% to 3%/8%; RR0.21; significant 
2%/8%; RR 0.28; significant 
- 
- 
- 
- 
- 
Low 
- 
Moderate 
Moderate 
Moderate 
Outcome: proportion of ≥15 ETDRS letters or ≥3 Snellen-lines gain or loss Pegaptanib (PG) 
Not measured 
Outcome: vision related quality of life (VFQ 25) Bevacizumab (IVB) and Pegaptanib (PG);  between groups difference 
Not measured 
Outcome: vision related quality of life (VFQ 25) Ranibizumab (RBZ);  between groups difference 
RBZ/MPC: 1/345/345 
RBZ+MPC/MPC: 1/345/345 
RCT 
RCT 
Ser. limit.¤ 
Ser. limit.¤ 
Only 1 trial 
Only 1 trial 
Direct 
Direct 
5.3; significant, clinic. relevant 
4.8; significant, clinic. relevant 
- 
- 
Moderate 
Moderate 
 
clinic. relev.: clinically relevant; def. MPC: deferred laser photocoagulation; ETDRS: Early Treatment of Diabetic Retinopathy Study; h. dose: high dose; IVB: intravitreal bevacizumab; IVT: in-
travitreal triamcinolone; l. dose: low dose; limit.: limitations; logMAR: logarithm of the minimal angle of resolution; MPC: macular laser photocoagulation; n.a.: not applicable: no ser. limit.: no seri-
ous limitations; ser.: serious; sign.: significant; *low incidence, lack of precise data, sparse data, strong or very strong association, high risk of publication bias, dose-efficacy gradient, residual con-
founding plausible; **≥30 letters loss; #uncertain whether effect of single dose is sustained for 24 ws; ## allocation concealment unclear, incomplete outcome data not addressed, imbalance of base-
line VA; ±sequence generation and allocation concealment unclear, blinding of outcome assessment unclear, incomplete outcome data not addressed, imbalance of disease severity at baseline; ±± al-
location concealment unclear, no blinding of outcome assessment, incomplete outcome data not addressed; incomplete data; incomplete outcome data handled with ‘last observation carried forward’; ¤ 
incomplete data; incomplete outcome data handled with ‘last observation carried forward’; ‡ incomplete outcome data handled with ‘last observation carried forward’; ‡‡ imbalance of  baseline VA, in-
complete outcome data; ¤¤ allocation concealment unclear, no blinding of outcome assessment, incomplete outcome data not addressed; incomplete data; 
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Table 5-2: Evidence profile: safety of anti-VEGF and comparators 
No of 
stud-
ies/eyes 
Design Limita-
tions 
Consistency 
of results 
Direct-
ness 
Effect size Other modifying 
factors* 
Quality of 
evidence 
Outcome: adverse events bevacizumab 
6/218 
 
RCT 
 
Serious 
limit.# 
 
Consistent 
 
Direct 
 
Ocular:  any event: 19%-48%; transient chamber reaction: 2%-20%; IOP: 0.2%; PDR: 2%-8%;  
Systemic: 0%-4%  
SAE:  IOP: 0.2%; Foot ulcer: 2%; cholecystectomy: 2%; no death 
Very low inci-
dence 
Very low 
Outcome: adverse events ranibizumab 
3/260 
 
RCT 
 
Serious 
limit.† 
 
Important 
inconsisten-
cies 
 
Direct 
 
Ocular: Any: 40%-80%; VH: 1%; endophtalmitis: 2%; retinal ischaemia/artery occlusion: 1% 
Systemic: Any: 14%-58%; cardiac: 7%; metabolism: 2%-4%; vascular: 4%; infections: 2% 
SAE: Any: 29%; death: 2%(2); VH: 1%-2%; cardiac: 7%; metabol.: 2%-4%; vasc.: 4%; infect.: 2%;  
endophtalmitis: 2%; retinal ischaemia/artery occlusion: 1% 
Very low inci-
dence  
Very low 
 
Outcome: adverse events pegaptanib 
1/128 
 
RCT 
 
Serious 
limit.¤ 
 
Only 1 trial 
 
Direct 
 
Ocular: Endophtalmitis: 0.15% per injection; 0.8 per subject; any event: 85% 
Systemic: No systemic AE 
SAE: Endophtalmitis: 0.15% per injection; 0.8 per subject; any event: 16% 
Very low inci-
dence 
 
Very low 
Outcome:  adverse events triamcinolone  
1/14 
 
 
RCT 
 
No seri-
ous limit. 
 
Only 1 trial 
 
Some 
uncert. 
 
Ocular: Increase of IOP 
Systemic: No systemic AE 
SAE: No  SAE 
Very low inci-
dence, sparse data
 
Very low 
 
Outcome:  adverse events laser photocoagulation 
5/555 
 
RCT 
 
Serious 
limit. #,† 
 
Consistent Direct 
 
Ocular: Any: 2%-53%; PDR: 3%-6%; neovasc.:3%; lens opacity: 2%; VH: 2%-9%; ocular vascular events: 0.4%; 
IOP:5% 
Systemic: Any: 4%-61%; fall: 3%; cardiac: 1%-4%; CVI: 3%; metabolism: 3%; vascular: 3%; infections: 3% 
SAE: Any: 2%-22%; VH: 3%-9%; death: 4%(2); ocular vascular events: 0.4%; IOP:5%; cardiac: 1%-4%; wors-
ening angina: 3%; CVI: 3%; foot ulcer: 3%; metabolism: 3%; vascular: 3%; infections: 3% 
Very low inci-
dence 
Very low 
 
Outcome:  adverse events sham injection 
3/127 RCT 
 
Serious 
limit.¤ 
Some incon-
sistencies 
Direct Ocular:  Any: 60%-70%; No injection related complication; retinal detachment: 2% 
Systemic: Any: 0%-12%; metabolism: 2%; vascular: 2%; infections: 3% 
SAE: Any: 15%; Death: 3% (1); IOP: 57%; retinal detachment: 2%; metabolism: 2%; vascular: 2%; infections: 
3% 
Very low inci-
dence 
Very low 
Outcome: adverse events bevacizumab + triamcinolone 
2/87 
 
RCT 
 
Serious 
limit.± 
Consistent Direct Ocular: IOP: 8%-16%; lens opacity: 0%-8%; VH:3%; PDR: 0%-8%; neovasc.: 8% 
Systemic: Not stated 
SAE: Death: 0% to 4% (2); VH: 1%; high risk PDR: 1% 
Very low inci-
dence 
 
Vey low 
 
Outcome: adverse events bevacizumab + photocoagulation 
1/22 RCT 
 
 
Serious 
limit.## 
 
Only 1 trial 
 
Some 
uncert. 
Ocular: No injection related complications 
Systemic: Not stated 
SAE: Not stated 
Very low inci-
dence, sparse data
Very low 
 
 
Outcome: adverse events ranibizumab + laser 
2/348 
 
RCT 
 
Serious 
limit.†† 
Consistent Direct Ocular: Any: 43%; VH: 2%; endophtalmitis: 0.5%; ocular vascular events: 0.2%; IOP: 4% 
Systemic: Any: 46%; cardiac: 0%-3%; metabolism: 2%; vascular: 1%-2%; infections: 3% 
SAE: Any: 2%-20%; VH: 2%; endophtalmitis: 0.5%; ocular vascular events: 0.2%; IOP: 4%; cardiac: 0%-3%; 
metabolism: 2%; vascular: 1%-2%; infections: 3% 
Very low inci-
dence 
 
Very low 
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AE: adverse event; CVI: cerebrovascular incidence; imp. inc.: important inconsistency; IOP: intraocular pressure; limit.: limitations; no imp. inc.: no important inconsistency; PDR: proliferative dia-
betic retinopathy; SAE: serious adverse event; uncert.: uncertainty; VH: vitreous haemorrhage; *low incidence, lack of precise data, sparse data, strong or very strong association, high risk of publica-
tion bias, dose-efficacy gradient, residual confounding plausible; #sequence generation and allocation concealment unclear, incomplete outcome data not addressed, blinding of outcome assessment 
unclear, imbalance of disease severity across groups at baseline; ‡allocation concealment unclear, no blinding of outcome assessment, incomplete outcome data not addressed; incomplete data; incom-
plete outcome data handled with ‘last observation carried forward’; ¤imbalance baseline VA, incomplete outcome data; ±allocation concealment unclear, incomplete outcome data not addressed, im-
balance of VA across groups at baseline; ##sequence generation and allocation concealment unclear, blinding of outcome assessment unclear, incomplete outcome data not addressed, imbalance of 
disease severity at baseline; ‡‡allocation concealment unclear, no blinding of outcome assessment, incomplete outcome data not addressed; incomplete data; 
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6 Discussion 
Current evidence has demonstrated that in a proportion of patients (on av-
erage 25%) VEGF-inhibitors result in better visual acuity than in patients 
treated with glucocorticoids or with laser photocoagulation. However, out-
comes have been measured for a maximum of one year and the number of 
injections required for long-term improvement as well as general long-term 
efficacy is unknown. 
Even though anti-VEGF treatment has shown better outcomes than alterna-
tive treatments we need to be aware that in every study that analysed the 
proportion of patients who gained a clinically relevant number of let-
ters/lines, the majority of patients (60% to 85%) did not achieve this im-
provement. Yet, this needs to be judged against the background that alterna-
tive therapies have primarily achieved stabilisation rather than improve-
ment so far.   
Concerning the different products there is tentative evidence supporting the 
use of intravitreal bevacizumab injections in the treatment of DME, however 
quality of evidence is on average lower and follow-up is shorter in those 
studies than in the studies on ranibizumab. There is slightly stronger evi-
dence supporting the use of intravitreal ranibizumab injections in the treat-
ment of DME, yet, most of the ‘ranibizumab-studies’ have severe limitations, 
too. Concerning pegaptanib there is insufficient evidence to support its use 
in DME.  
When comparing the products we need, however be aware that studies dif-
fered considerably concerning pre-entry treatment of the study population, 
number of doses and follow-up periods. Additionally, this limits transfer-
ability of study results into general practice.   
Overall, high quality trials on bevacizumab included patients with refractory 
DME while in the ranibizumab trials inclusion was defined by the time pe-
riod to prior treatment rather than by failure of prior treatment.  
In the bevacizumab studies patients mostly received a limited number of in-
jections (some only one) while in the majority of ranibizumab trials the 
number of doses was unlimited. This may bias the results in favour of 
ranibizumab.  
Follow-up was on average longer (1 year) in the ranibizumab trials than in 
the bevacizumab studies (6 months), hence 1-year benefits need yet to be 
demonstrated for bevacizumab. However, overall 1 year is a rather short 
time period for a chronic disease such as diabetic retinopathy and we still 
know little about long-term benefits or risks from this treatment. 
Concerning safety, the design of the studies and the number of patients is 
not suitable to detect rare adverse events. Hence, while neither study dem-
onstrated serious safety problems, evidence is not sufficient to regard the 
products as safe in patients with DME.  This relates to all three products 
analysed. Consequently, observational studies with a large number of pa-
tients and long-term follow-ups are needed. Large databases from age-
related macular degeneration (AMD)-studies provide reassurance on the 
safety of intravitreal injections of ranibizumab [4] and bevacizumab [28, 29], 
however patient characteristics differ between those suffering from diabetic 
macular oedema and those with AMD. 
more patients (¼) 
achieve improved VA 
than after alternative 
treatments 
for small group progress 
because so far mainly 
stabilisation 
slightly stronger 
evidence for RBZ than 
IVB efficacy 
Pegaptanib unclear 
different study designs 
make comparison 
difficult 
IVB-studies: patients 
with refractory DME, 
not so in RBZ-studies 
IVB-studies: limited 
number of injections,  
bias towards RBZ 
longer follow-up in 
RBZ-trials 
safety: long-term 
observational studies 
required 
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While off-label use of a product is definitely problematic, the 16-fold higher 
price per injection of ranibizumab compared to bevacizumab warrants 
health economic discussions. In a previous report [30] it was demonstrated 
that in a single clinic 1,800 more injections per year could be administered 
from the same resources available because bevacizumab was used in addition 
to ranibizumab instead of using the licensed product only. Vice versa, addi-
tional costs of 700.000 € would have occurred if ranibizumab only had been 
used. Hence, a much higher number of patients can be treated if bevacizu-
mab is used.  
Our results are congruent with recent reviews [4, 6, 8, 31, 32]. Most impor-
tantly, while it was confirmed that ranibizumab is efficacious in the treat-
ment of DME in a very recent NICE report, its use was not recommended 
for cost-effectiveness reasons [4].  
Finally, many studies are currently ongoing. A recent NICE-review identi-
fied 22 studies on ranibizumab of which only one (non-industry-sponsored) 
compares ranibizumab against bevacizumab [4]. Furthermore there are 
eight ongoing trials on bevacizumab and five on pegaptanib. Re-evaluation 
at a later stage is highly recommended.  
7 Conclusion 
Overall, for some patients with DME, VEGF-inhibitors seem to be a more ef-
fective short-term treatment than alternative therapies. Regardless of the 
registration status, the efficacy profile of anti-VEGF in patients with dia-
betic macular oedema is slightly in favour of ranibizumab, however, prod-
ucts have not been evaluated head-to-head so far and studies differ consid-
erably concerning number of anti-VEGF doses and prior treatment. Hence, 
our evidence does not support superiority of one anti-VEGF over another. 
Concerning safety, the limited evidence available does not suggest serious 
safety problems in any of the products, yet the evidence is not of sufficient 
quality to confirm safety. Decision on financing should take into account the 
high price-difference between the products and the fact that many studies 
are still ongoing.  
 
 
 
economic issues: more 
patients can be treated 
with IVB due to large 
price difference 
NICE: RBZ not 
recommended for cost-
effectiveness reasons 
many studies ongoing 
short-term efficacy of 
anti-VEGF for small 
group of patients  
data don’t suggest 
superiority of a single 
product, safety unclear  
decision makers should 
take price differences 
and ongoing studies 
into account 
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9 Appendix: Search strategy 
Medline via Ovid: 
Database: Ovid MEDLINE(R) <1948 to January Week 2 2011>, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations <January 24, 2011>, Ovid MEDLINE(R) Daily Update <January 24, 2011>, Ovid 
OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Diabetic Retinopathy/ (15692) 
2     Diabetic Retinopathy.mp. (18713) 
3     Diabetic macular oedema*.mp. (189) 
4     Diabetic macular edema*.mp. (927) 
5     *Macular Edema/ (2118) 
6     (diabetic adj Macular Edema).mp. (925) 
7     (diabetic adj Macular Oedema).mp. (189) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (19993) 
9     Anti-VEGF*.mp. (1665) 
10     Anti vascular endothelial growth factor*.mp. (471) 
11     VEGF-inhibitor*.mp. (248) 
12     Bevacizumab.mp. (4422) 
13     Avastin.mp. (684) 
14     Ranibizumab.mp. (681) 
15     Lucentis.mp. (124) 
16     Pegaptanib.mp. (360) 
17     vascular endothelial growth factor inhibitor*.mp. (63) 
18     9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (6508) 
19     8 and 18 (540) 
*************************** 
25.01.2011: Embase Session Results 
....................................................... 
No.  Query Results                Results   Date        
#24. #8 AND #23         594    26 Jan 2011 
#23. #9 OR #10 OR #11 OR #12 OR #13 OR      4,372    26 Jan 2011 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
#22. 'vascular endothelial growth factor inhibitors'    51    26 Jan 2011 
#21. 'vascular endothelial growth factor inhibitor'  37    26 Jan 2011 
#20. 'pegaptanib'/exp/dd_vi            436    26 Jan 2011 
#19. 'lucentis'/exp/dd_vi           661    26 Jan 2011 
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#18. 'ranibizumab'/exp/dd_vi         661     26 Jan 2011 
#17. 'avastin'/exp/dd_vi          1,366     26 Jan 2011 
#16. 'bevacizumab'/exp/dd_vi       1,366     26 Jan 2011 
#15. 'vegf-inhibitors'            233     26 Jan 2011 
#14. 'vegf-inhibitor'       145     26 Jan 2011 
#13. 'vasculotropin inhibitor'/exp/dd_vi    127     26 Jan 2011 
#12. 'anti vascular endothelial growth factors'    4     26 Jan 2011 
#11. 'anti vascular endothelial growth factor'      529    26 Jan 2011 
#10. 'anti vegfs'           7     26 Jan 2011 
#9.  'anti vegf'             2,034     26 Jan 2011 
#8.  #1 OR #2 OR #3 OR #4 OR #5 OR #6      25,791     26 Jan 2011 
#7.  'diabetic macular oedemas'          26 Jan 2011 
#6.  'diabetic macular edemas'             3     26 Jan 2011 
#5.  'diabetic macular edema'          1,590     26 Jan 2011 
#4.  'diabetic macular oedema'           218     26 Jan 2011 
#3.  'diabetic macular edema'/exp       942     26 Jan 2011 
#2.  'diabetic retinopathy'           25,130    26 Jan 2011 
#1.  'diabetic retinopathy'/exp        22,447    26 Jan 2011 
....................................................... 
 
 
 
26.01.2011:  CRD (DARE-NHS EED-HTA): 
 
MeSH Diabetic Retinopathy EXPLODE 1 2 3 
"Diabetic Retinopathy" 
"Diabetic macular oedema" 
"Diabetic macular edema" 
MeSH Macular Edema EXPLODE 1 
diabet* NEAR "Macular Oedema" 
diabet* NEAR "Macular Edema" 
#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
Anti-VEGF* 
"Anti vascular endothelial growth factor" 
"Anti vascular endothelial growth factors" 
VEGF-inhibitor* 
Bevacizumab 
Avastin 
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Ranibizumab 
Lucentis 
Pegaptanib 
"vascular endothelial growth factor inhibitor" 
"vascular endothelial growth factor inhibitors" 
#9 OR #10 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
#8 AND #20 
13 Hits 
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Search Name:   Anti-VEGF bei diabetischem Makularödem 
Comments:       MEL 2011  
Save Date:       2011-01-26 06:28:26.92 
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#21 (#8 AND #20) 
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